Revised analysis (2) conducted by ScHARR 'Routine antenatal anti-D prophylaxis for RhD-negative women (review)'

This analysis was recalculated at the request of the Committee to consider giving RAADP to all women who are RhD negative, irrespective of the number of previous pregnancies, compared with not using RAADP. The same assumptions that were used in revised analysis (1) were also used for these analyses.

Table 28c: Incremental cost-effectiveness outcomes associated with RAADP for primigravidae compared with no RAADP

Anti-D dose	Total cost	No. of sensitisations avoided	No. of affected pregnancies avoided	No. of foetal losses avoided	LYG	QALYs gained	Cost per sensitis-ation avoided	Cost per affected pregnancy avoided	Cost per foetal loss avoided	Cost per LYG	Cost per QALY gained
Baseline value	£1,796,546	630	353	14.14	2878879	2533443					
2x500 IU (D-Gam)	£2,360,604	162	150	6	152	121	£14,561	£15,783	£394,580	£15,532	£19,438
2x1250 IU (Partobulin)	£3,081,262	162	150	6	152	121	£19,006	£20,602	£515,040	£20,274	£25,372
1x1500 IU (Rhopylac)	£1,797,590	162	150	6	152	121	£11,088	£12,019	£300,471	£11,828	£14,802
1x1500 IU (WinRho)	£13,823,575	162	150	6	152	121	£85,267	£92,426	£2,310,641	£90,957	£113,827

Table 29c: Incremental cost-effectiveness outcomes associated with RAADP for multigravidae and primigravidae compared with no RAADP

Anti-D dose	Total cost	No. of sensitisations avoided	No. of affected pregnancies avoided	No. of foetal losses avoided	LYG	QALYs gained	Cost per sensitis-ation avoided	Cost per affected pregnancy avoided	Cost per foetal loss avoided	Cost per LYG	Cost per QALY gained
2x500 IU	£5,005,724	395	222	9	225	180	£12,673	£22,581	£564,524	£22,222	£27,810

(D-Gam)											
2x1250 IU (Partobulin)	£6,538,609	395	222	9	225	180	£16,553	£29,496	£737,396	£29,027	£36,326
1x1500 IU (Rhopylac)	£3,808,158	395	222	9	225	180	£9,641	£17,179	£429,467	£16,906	£21,156
1x1500 IU (WinRho)	£29,388,169	395	222	9	225	180	£74,401	£132,571	£3,314,269	£130,464	£163,268